Clinical Trials
Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19
Vir Biotechnology, Inc. and GlaxoSmithKline plc announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early) study evaluating VIR-7831 for the early treatment of COVID-19 in patients who are...
Press Releases
BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2
Pfizer Inc. and BioNTech SE announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lead candidate from the companies’ vaccine development program against COVID-19. The EMA’s decision to start a rolling review...
Press Releases
TraceLink VRS Solution Implemented by Henry Schein Months Ahead of Deadline for DSCSA Saleable Returns Verification Requirement
TraceLink Inc., the leading digital platform company for the life sciences supply chain, announced that Henry Schein, the world's largest provider of health care solutions to office-based dental and medical practitioners, has implemented TraceLink's verification router service (VRS) solution....
Press Releases
Catalent Launches OneXpress Solution to Accelerate Oral Dosage Products from Clinic to Launch
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced the launch of its new OneXpress™ service for the integrated development, scale up and...
Drug Research
Syngene joins global industry consortium to accelerate collaborative research in COVID-19 testing
Syngene International Limited announced that it has joined a global consortium of 19 organizations from the healthcare industry, led by Bristol Myers Squibb, to help inform, improve and accelerate various aspects of COVID-19 testing, ranging from research to clinical...
Clinical Trials
FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients
FSD Pharma Inc. announced that the U.S. FDA has authorized the initiation of a Phase 2 study for the use of FSD201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat COVID-19, the disease caused by the SARS-CoV-2 virus (the “FSD201...
IT & Data Management
AARDEX Group partners with BIOCORP to extend digital solutions for precision medication adherence
Belgium-based AARDEX Group, the world leader in medication adherence solutions, announced a strategic partnership with BIOCORP, a French company specialized in the design, development and manufacture of innovative medical devices. The alliance will further extend the comprehensive portfolio of...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.















